Biotechnik Gmb News Today : Breaking News, Live Updates & Top Stories | Vimarsana

PROGEN signs non-exclusive distribution agreement for sales of research antibody products

Share this article Share this article HEIDELBERG, Germany, April 29, 2021 /PRNewswire/ PROGEN Biotechnik GmbH, established manufacturer of premium research antibodies and AAV gene therapy tools, has signed a non-exclusive distribution agreement with Thermo Fisher Scientific for selected proprietary antibodies, including top-selling immunochemicals. PROGEN is an established manufacturer of over 1.000 research antibodies for basic and applied science (PRNewsfoto/PROGEN Biotechnik GmbH) Since 1983, PROGEN has developed a widely cited portfolio of over 1.000 primary and secondary antibodies for basic and applied life sciences. Sales channels include the company s online shop and the collaboration with global distributors. As a leading supplier of research materials, Thermo Fisher will now offer a choice of 371 primary antibodies globally. Among them are top-selling products in biomedical research and development, such as lipid metabolism, cytoskeleton, cell adhesion, or oncology t

Biotechnik gmbKatja bettsMaik landerJoint managing directors katja bettsProgen biotechnik gmbh

PROGEN signs non-exclusive distribution agreement for sales of research antibody products

PROGEN signs non-exclusive distribution agreement for sales of research antibody products
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

Biotechnik gmbKatja bettsMaik landerJoint managing directors katja betts

Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic continues to spread with devastating consequences. For passive immunization efforts, nanobodies have size and cost advantages over conventional antibodies. Here, we generated four neutralizing nanobodies that target the receptor-binding domain of the SARS-CoV-2 spike protein. We defined two distinct binding epitopes using x-ray crystallography and cryo-electron microscopy. Based on the structures, we engineered multivalent nanobodies with more than 100-fold improved neutralizing activity than monovalent nanobodies. Biparatopic nanobody fusions suppressed the emergence of escape mutants. Several nanobody constructs neutralized through receptor-binding competition, while other monovalent and biparatopic nanobodies triggered aberrant activation of the spike fusion machinery. These premature conformational changes in the spike protein forestalled productive fusion, and rendered the virions non-infectious.

United statesBaden wubergNordrhein westfalenKarolinska institutetMyone streptavidinStephan poehlmannLandesuntersuchungsamt rheinland pfalzBiotechnik gmbConnie cepkoSean whelanRalf bartenschlagerMicroplates perkin elmerDidier tronoWorld reference centerBiacore insight evaluation softwareGe healthcare life sciences